Glenmark Pharma is currently trading at Rs. 321.50, up by 0.10 points or 0.03% from its previous closing of Rs. 321.40 on the BSE.
The scrip opened at Rs. 323.50 and has touched a high and low of Rs. 324.85 and Rs. 313.00 respectively. So far 28843 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 389.75 on 07-Dec-2010 and a 52 week low of Rs. 241.60 on 28-Feb-2011.
Last one week high and low of the scrip stood at Rs. 332.10 and Rs. 313.00 respectively. The current market cap of the company is Rs. 8689.97 crore.
The promoters holding in the company stood at 48.30% while Institutions and Non-Institutions held 38.09% and 13.60% respectively.
Glenmark Pharmaceuticals has got a tentative approval from the US Food and Drug Administration (US FDA) for its zolmitriptan pill, the generic version of AstraZeneca Plc.’s Zomig anti-migraine medicine.
Earlier in August, Glenmark Pharmecuaticals’ novel chemical entity “Revamilast” initiated Phase II B human dose range finding trial globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
Glenmark Pharmecuaticals is research driven globally integrated pharmaceuticals company headquartered in Mumbai. It is leading player in the discovery of new molecules both NCEs (New chemical entity) and NBEs (New biological entity).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1846.95 |
Dr. Reddys Lab | 1350.65 |
Cipla | 1490.55 |
Lupin | 2357.75 |
Zydus Lifesciences | 961.75 |
View more.. |